AC Immune Ltd (ACIU)

Currency in USD
2.170
-0.280(-11.43%)
Closed·
After Hours
2.1700.000(0.00%)
·
ACIU Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ACIU is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.1002.400
52 wk Range
1.4303.980
Key Statistics
Prev. Close
2.45
Open
2.4
Day's Range
2.1-2.4
52 wk Range
1.43-3.98
Volume
152.58K
Average Volume (3m)
136.36K
1-Year Change
-29.8%
Book Value / Share
0.95
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ACIU Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.373
Upside
+331.92%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

AC Immune Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

AC Immune Ltd Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company’s SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer’s disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson’s disease; and ACI-35.030, designs to stimulate a patient’s immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Compare ACIU to Peers and Sector

Metrics to compare
ACIU
Peers
Sector
Relationship
P/E Ratio
−3.4x−2.7x−0.5x
PEG Ratio
−0.15−0.020.00
Price/Book
2.3x1.2x2.6x
Price / LTM Sales
6.0x5.2x3.3x
Upside (Analyst Target)
296.9%560.9%42.8%
Fair Value Upside
Unlock5.7%6.5%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 9.373
(+331.92% Upside)

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
-0.21 / -0.1742
Revenue / Forecast
1.31M / 1.98M
EPS Revisions
Last 90 days

ACIU Income Statement

People Also Watch

16.24
SRPT
-3.04%
4.190
ATAI
+1.21%
0.413
ADIL
-4.88%
2.2600
DARE
-5.83%
2.76
INMB
+2.60%

FAQ

What Stock Exchange Does AC Immune Trade On?

AC Immune is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for AC Immune?

The stock symbol for AC Immune is "ACIU."

What Is the AC Immune Market Cap?

As of today, AC Immune market cap is 213.72M.

What Is AC Immune's Earnings Per Share (TTM)?

The AC Immune EPS (TTM) is -0.50.

When Is the Next AC Immune Earnings Date?

AC Immune will release its next earnings report on 13 Nov 2025.

From a Technical Analysis Perspective, Is ACIU a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has AC Immune Stock Split?

AC Immune has split 0 times.

How Many Employees Does AC Immune Have?

AC Immune has 153 employees.

What is the current trading status of AC Immune (ACIU)?

As of 06 Aug 2025, AC Immune (ACIU) is trading at a price of 2.17, with a previous close of 2.45. The stock has fluctuated within a day range of 2.10 to 2.40, while its 52-week range spans from 1.43 to 3.98.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.